Skip to main content
. Author manuscript; available in PMC: 2023 Jun 1.
Published in final edited form as: Arthritis Rheumatol. 2022 Apr 27;74(6):948–960. doi: 10.1002/art.42074

Figure 1. LSD1 is required for osteoclast differentiation.

Figure 1.

A, Osteoclast precursors (OCPs) derived from human CD14-positive monocytes were treated with 40 ng/ml RANKL. TRAP-positive, multinucleated cells were counted in triplicate. Left panel, representative results from one of three independent donors. Right panel, number of TRAP-positive, multinucleated cells. Data are shown as mean ± SEM from aggregate data from three independent donors. B, RT-qPCR analysis of osteoclast-related genes (normalized relative to TBP mRNA). OCPs were treated with RANKL for 48 h. Data are mean ± SEM of triplicates from one representative experiment of three independent donors. C, Human CD14-positive monocytes were nucleofected with LSD1-specific or scrambled control siRNAs, and osteoclast were generated. TRAP-positive, multinucleated cells were counted in triplicate. Left panel, representative results from three independent experiments. Right panel, number of TRAP-positive, multinucleated cells. Data are shown as mean ± SEM from aggregate data from three independent donors. D, RT-qPCR analysis of osteoclast-related gene expression. Data are mean ± SEM of triplicates from one representative experiment of three independent experiments.

* p < 0.05, using the Tukey-Kramer test.